Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

Autor: Frank Griesinger, MD, PhD, Wilfried E.E. Eberhardt, MD, PhD, Wolfgang M. Brueckl, MD, PhD, Horst-Dieter Hummel, MD, PhD, Bastian Jaeschke, MD, Jens Kern, MD, Claas Wesseler, MD, Martina Jänicke, PdD, Annette Fleitz, PhD, Stefan Zacharias, PhD, Annette Hipper, PhD, Annika Groth, MD, PhD, Wilko Weichert, MD, PhD, Steffen Dörfel, Volker Petersen, MD, Jan Schröder, MD, Jochen Wilke, MD, Martin Sebastian, MD, Michael Thomas, MD, PhD, Juliana Ababei, Jürgen Alt, Andreas Ammon, Jürgen Anhuf, Ivo Azeh, Stefan Bauer, Dirk Behringer, Winfried Berger, Christiane Bernhardt, Mathias Bertram, Michael Boesche, Sabine Bohnet, Harald-Robert Bruch, Wolfgang Brückl, Ulrike Burkhard-Meier, Petros Christopoulos, Klaus-Ulrich Däßler, Maike de Wit, Tobias Dechow, Reinhard Depenbusch, Lutz Dietze, Markus Dommach, Wilfried Eberhardt, Corinna Elender, Wolfgang Elsel, Till-Oliver Emde, Martin Faehling, Thomas Fietz, Jürgen R. Fischer, Dimitri Flieger, Anke Freidt, Werner Freier, Christian Frenzel, Florian Fuchs, Roswitha Fuchs, Tobias Gaska, Wolfgang Gleiber, Christian Grah, Frank Griesinger, Christian Grohé, Matthias Groschek, Björn Güldenzoph, Andreas Günther, Siegfried Haas, Matthias Hackenthal, Volker Hagen, Lars Hahn, Verena Hannig Carla, Richard Hansen, Hanns-Detlev Harich, Monika Heilmann, Kathrin Heinrich, Christiane Hering-Schubert, Jörg Heßling, Petra Hoffknecht, Patricia Hortig, Gerdt Hübner, Horst-Dieter Hummel, Ulrich Hutzschenreuter, Thomas Illmer, Georg Innig, Bastian Jaeschke, Christian Junghanß, Ulrich Kaiser, Haytham Kamal, Kato Kambartel, Jens Kern, Martin Kimmich, Dorothea Kingreen, Heinz Kirchen, Martine Klausmann, Ortwin Klein, Konrad Kokowski, Wolfgang Körber, Cornelius Kortsik, Dirk Koschel, Benoit Krämer, Beate Krammer-Steiner, Eckart Laack, Christof Lamberti, Rumo David Leistner, Christoph Losem, Andreas Lück, Christoph Maintz, Kerstin Martin, Dirk Medgenberg, Martin Metzenmacher, Christian Meyer zum Büschenfelde, Philipp Meyn, Enno Moorahrend, Annette Müller, Lothar Müller, Michael Neise, Holger Nückel, Arnd Nusch, Tobias Overbeck, Henning Pelz, Volker Petersen, Bettina Peuser, Margarete Plath, Winfried J. Randerath, Jacqueline Rauh, Martin Reck, Dietmar Reichert, Niels Reinmuth, Marcel Reiser, Roland Repp, Daniel Reschke, Achim Rittmeyer, Yolanda Rodemer, Sandra Sackmann, Parvis Sadjadian, Reiner Sandner, Annette Sauer, Harald Schäfer, Christoph Schaudt, Rudolf Schlag, Burkhard Schmidt, Stephan Schmitz, Jan Schröder, Michael Schroeder, Mathias Schulze, Christian Schumann, Wolfgang Schütte, Martin Schwaiblmair, Florian Schwindt Peter, Martin Sebastian, Bernd Seese, Gernot Seipelt, Thomas Sorgenfrei, Johannes Steiff, Heike Steiniger, Tanja Trarbach, Amanda Tufman, Jens Uhlig, Ursula Vehling-Kaiser, Eyck von der Heyde, Ulla von Verschuer, Cornelius Waller, Thomas Wehler, Georg Weißenborn, Florian Weißinger, Martin Wermke, Claas Wesseler, Jörg Wiegand, Stefan Wilhelm, Jochen Wilke, Mark-Oliver Zahn, Matthias Zaiss, Matthias Zeth

Publikováno v: JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100626- (2024)

Introduction: Patients with metastatic NSCLC (mNSCLC) treated with immune checkpoint inhibitors in clinical practice may often not meet the strict inclusion criteria of clinical trials. Our aim was to assess the trial eligibility of patients with mNS

Externí odkaz: https://doaj.org/article/193c505adea04fdda590997c6e7e69c0

Cetuximab biweekly (q2w) plus mFOLFOX6 as 1st line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC) – Primary endpoint and subgroup analysis of the CEBIFOX trial

Autor: Tanja Trarbach, Thomas Herold, Gabriele Linden, Saskia Ting, Karl Worm, Karina Kostbade, Peter Markus, Johannes Meiler, Brigitte Schumacher, Heike Knipp, Stefan Kasper, H.T. Steinmetz, Peter Reimer, Martin Schuler, T. Höhler, Kurt Werner Schmid, Winfried Berger, Andreas Paul, Alexander Dechêne

Publikováno v: Annals of Oncology. 27:vi167

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::033e7056cc233ee132703dd9ae54561e
https://doi.org/10.1093/annonc/mdw370.56

Cetuximab biweekly plus mFOLFOX6 as first-line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC): Primary endpoint and subgroup analysis of the CEBIFOX trial

Autor: Karina Kosbade, Kurt Werner Schmid, Tilman Steinmetz, Peter Reimer, Thomas Herold, Johannes Meiler, Martin Schuler, Tanja Trarbach, Saskia Ting, Andreas Paul, Winfried Berger, Brigitte Schumacher, Gabriele Linden, Alexander Dechêne, Karl Worm, Stefan Kasper, Heike Knipp, Thomas Hoehler, Peter Markus

Publikováno v: Journal of Clinical Oncology. 33:3568-3568

3568 Background: The multicenter, single-arm, phase II CEBIFOX trial (Simon`s two stage minimax design) evaluated the efficacy of mFOLFOX6 + biweekly cetuximab (500 mg/m2) as 1st line therapy in KR...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::773bb2cedb4cf40e6a55de6a433b8bb6
https://doi.org/10.1200/jco.2015.33.15_suppl.3568

Die Doppelsaccharosetrennwandtechnik: Eine Methode zur Untersuchung des Membranpotentials und der Membraneigenschaften glatter Muskelzellen

Autor: Winfried Berger

Publikováno v: Pflügers Archiv - European Journal of Physiology. 277:570-576

Es wird eine Versuchsanordnung einer Doppelsaccharosetrennwand beschrieben, mit deren Hilfe Membranpotentialanderungen und Membraneigenschaften glatter Muskelzellen in einem sehr kleinen und scharf begrenzten Abschnitt untersucht werden konnen. Beweg

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bfd34b8f469563399cec878dfa27f282
https://doi.org/10.1007/bf00363179

Pacemaker activity in the circular smooth muscle of frog stomach

Autor: Winfried Berger, G. P. Dahl

Publikováno v: Pflugers Archiv : European journal of physiology. 351(2)

Wick and pressure electrode recording were used to locate the sites where spontaneous activity originates in isolated bundles of the circular smooth muscle layer of frog stomach. In long bundles up to three pacemaker regions were found to be active.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::286fe341e6692e74f26ad7c6d27a2f18
https://pubmed.ncbi.nlm.nih.gov/4547530